ARID1A deficiency can also lead to mismatch repair defects, replication stress, and genomic instability, making ARID1A-mutant cancers vulnerable to specific therapies, including PARP inhibitors, EZH2 inhibitors, BET inhibitors, and ATR inhibitors [25]. Here, PARP1 is linked to cancer.